(Q40098409)

17 September 2017

title

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome (English)

1 reference

17 September 2017

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Stephen Devereux

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Christopher P Fox

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Elizabeth Soilleux

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Toby A Eyre

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ruth Clifford

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Adrian Bloor

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Lucy Boyle

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Corran Roberts

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Maite Cabes

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

George Follows

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

John Gribben

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Chris S Hatton

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Tim J Littlewood

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Helen McCarthy

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Jim Murray

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Andrew R Pettitt

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Basile Stamatopoulos

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sharon B Love

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Anna Schuh

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Peter Hillmen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Andrew Wotherspoon

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

5 July 2016

1 reference

British Journal of Haematology

17 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

175

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

43-54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma

10 June 2020

cites work

1 reference

Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature

21 January 2018

1 reference

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.

21 January 2018

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome

21 January 2018

1 reference

Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome

21 January 2018

1 reference

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia

21 January 2018

1 reference

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

21 January 2018

1 reference

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation

21 January 2018

1 reference

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

21 January 2018

1 reference

2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation.

21 January 2018

1 reference

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients

21 January 2018

1 reference

Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome

21 January 2018

1 reference

The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation.

21 January 2018

1 reference

Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group

21 January 2018

1 reference

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders

21 January 2018

1 reference

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

21 January 2018

1 reference

Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation

21 January 2018

1 reference

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome

21 January 2018

1 reference

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.14177

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference